Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P180007/S015

Spiration Valve System (SVS)

Gyrus Acmi, Inc. · Decision date May 7, 2026

FDA DECISIONP180007/S015

What did the FDA decide?

FDA records P180007/S015 as a supplement to PMA P180007, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 7, 2026.

FDA approval order statement

The firm is submitting this 30-Day Notice of a change in the verification and validation process of the Water Treatment System. The firm is adding endotoxin testing for the water samples and related process modifications to the manufacturing work instruction.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Anesthesiology
Decision date
May 7, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P180007/S015
Regulatory pathway
PMA supplement
Product code
NJK
Decision code
OK30
Decision date
May 7, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Valve, pulmonary.

Product code
NJK
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P180007/S015 received

    Application receipt date recorded by FDA.

  2. P180007/S015 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P180007. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P180007

Product / regulatory recordCompanyPathwayDecision dateSource
Gyrus Acmi, Inc.PMA supplementAug 20, 2026FDA

Explore the linked device profile

Other records with product code NJK

Product / regulatory recordCompanyPathwayDecision dateSource
Pulmonx CorporationPMA supplementSep 11, 2026FDA
Pulmonx CorporationPMA supplementJun 17, 2026FDA
Pulmonx CorporationPMA supplementMar 17, 2026FDA
Pulmonx CorporationPMA approvalJun 29, 2018FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Gyrus Acmi, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6675 185th Ave. NE, Redmond, WA, 98052

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records